DeSante KA - Search Results

1

Sides GD, Cerimele BJ, Black HR, Busch U, DeSante KA. Sides GD, et al. Among authors: desante ka. J Antimicrob Chemother. 1993 Mar;31 Suppl C:65-75. doi: 10.1093/jac/31.suppl_c.65. J Antimicrob Chemother. 1993. PMID: 8478313 Review.

2

Pharmacokinetics of dirithromycin in patients with impaired hepatic function.

LaBreque D, Johlin F, Janda R, Shreves T, Gereats D, DeSante K, Cerimele B, Lanier T, Sides G. LaBreque D, et al. J Antimicrob Chemother. 1993 Nov;32(5):741-50. doi: 10.1093/jac/32.5.741. J Antimicrob Chemother. 1993. PMID: 8125838

3

Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo.

Goldberg MJ, Ring B, DeSante K, Cerimele B, Hatcher B, Sides G, Wrighton S. Goldberg MJ, et al. J Clin Pharmacol. 1996 Dec;36(12):1154-60. doi: 10.1002/j.1552-4604.1996.tb04170.x. J Clin Pharmacol. 1996. PMID: 9013373 Clinical Trial.

4

Pharmacokinetics of cefaclor AF: effects of age, antacids and H2-receptor antagonists.

Satterwhite JH, Cerimele BJ, Coleman DL, Hatcher BL, Kisicki J, DeSante KA. Satterwhite JH, et al. Among authors: desante ka. Postgrad Med J. 1992;68 Suppl 3:S3-9. Postgrad Med J. 1992. PMID: 1287615 Clinical Trial.

5

A comprehensive review of the clinical pharmacology and pharmacokinetics of cefaclor.

Sides GD, Franson TR, DeSante KA, Black HR. Sides GD, et al. Among authors: desante ka. Clin Ther. 1988;11 Suppl A:5-19. Clin Ther. 1988. PMID: 3072086 Review. No abstract available.

6

The penetration of dirithromycin into bronchoalveolar lavage fluid and alveolar macrophages.

Baughman RP, DeSante KA, Lanier TL, Conforti PM, Sides GD. Baughman RP, et al. Among authors: desante ka. J Antimicrob Chemother. 1994 May;33(5):1045-50. doi: 10.1093/jac/33.5.1045. J Antimicrob Chemother. 1994. PMID: 8089052 Clinical Trial. No abstract available.

7

Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin.

Bachmann K, Nunlee M, Martin M, Sullivan T, Jauregui L, DeSante K, Sides GD. Bachmann K, et al. J Clin Pharmacol. 1990 Nov;30(11):1001-5. doi: 10.1002/j.1552-4604.1990.tb03586.x. J Clin Pharmacol. 1990. PMID: 2243147

8

Effects of renal dysfunction on the pharmacokinetics of loracarbef.

Therasse DG, Farlow DS, Davidson RL, Quadracci LJ, Hatcher BL, Cerimele BJ, DeSante KA. Therasse DG, et al. Among authors: desante ka. Clin Pharmacol Ther. 1993 Sep;54(3):311-6. doi: 10.1038/clpt.1993.152. Clin Pharmacol Ther. 1993. PMID: 8375126

9

Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies.

Basson RP, Cerimele BJ, DeSante KA, Howey DC. Basson RP, et al. Among authors: desante ka. Pharm Res. 1996 Feb;13(2):324-8. doi: 10.1023/a:1016019904520. Pharm Res. 1996. PMID: 8932457 Clinical Trial.

10

Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate.

Basson RP, Ghosh A, Cerimele BJ, DeSante KA, Howey DC. Basson RP, et al. Among authors: desante ka. Pharm Res. 1998 Feb;15(2):276-9. doi: 10.1023/a:1011974803996. Pharm Res. 1998. PMID: 9523315

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page